FFA
CLRB icon

First Foundation Advisors’s Cellectar Biosciences CLRB Stock Holding History

First Foundation Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$16K – 455
2021
Q1 		$16K Buy
+33
New +$19.6K ﹤0.01% 413

Other funds holding CLRB

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

First Foundation Advisors's CLRB Position: Q2 2021 in Review

First Foundation Advisors sold out of Cellectar Biosciences (CLRB) in Q2 2021, closing a stake of 33 shares — an estimated $16K sold.

First Foundation Advisors first reported a position in CLRB in Q1 2021 and held it in 1 quarter. The position peaked at $16K in Q1 2021. 43 funds tracked by Wall St. Rank hold CLRB as of Q2 2021.

  • First Foundation Advisors reported no remaining Cellectar Biosciences position as of Q2 2021 after selling out during the quarter.
  • First Foundation Advisors sold 33 Cellectar Biosciences shares in Q2 2021, an estimated $16K.
  • First Foundation Advisors first reported a position in Cellectar Biosciences in Q1 2021 and held it in 1 quarter.
  • First Foundation Advisors's Cellectar Biosciences position peaked at $16K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2021.

Based on First Foundation Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.